

Peptides compounds for delivering active agents across the blood-brain barrier

Patent number: NZ507275
Publication date: 2001-11-30
Inventor: LEONE-BAY ANDREA; HO KOC-KAN; LEIPOLD HARRY R; MILSTEIN SAM J; GSCHNEIDNER DAVID; SARUBBI DONALD J; WANG ERIC
Applicant: EMISHERE TECHNOLOGIES INC
Classification:
- International: C07C233/83
- european:
Application number: NZ200000507275 20001003
Priority number(s): US19970796335 19970207; NZ200000337131 20001003; US19970796334 19970207; US19970797100 19970207; US19970797816 19970207; US19970796338 19970207; US19970796340 19970207; US19970796336 19970207; US19970797813 19970207; US19970797820 19970207; US19970796337 19970207; US19970796341 19970207; US19970797817 19970207; US19970796339 19970207

Report a data error here

Abstract of NZ507275

A composition or salt thereof is described comprising: at least one active agent, and a compound, 8(N-2-Hydroxy-4-methoxybenzoyl) aminocaprylic acid (as shown). The biologically active agent could be interferon, interleukin-1, interleukin-II, insulin, heparin, calcitonin, oxytocin, vasopressin, vancomycin, desferrioxamine, parathyroid hormone, or any combination thereof. This composition is to be passed across a mammalian blood/brain barrier.

Data supplied from the esp@cenet database - Worldwide

BEST AVAILABLE COPY

1946/2C892

COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS**FIELD OF THE INVENTION**


5 The present invention relates to compounds for delivering active agents, and particularly biologically or chemically active agents. These compounds are used as carriers to facilitate the delivery of a cargo to a target. The carrier compounds are well suited to form non-covalent mixtures with biologically-active agents for oral administration to animals. Methods for the preparation and administration of such compositions are also disclosed.

10

BACKGROUND OF THE INVENTION

Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through which delivery occurs, 15 the environment of the target for delivery, or the target itself. Biologically or chemically active agents are particularly vulnerable to such barriers.

For example in the delivery to animals of biologically active or chemically active pharmacological and therapeutic agents, barriers are imposed by the body. Examples of physical barriers are the skin and various 20 organ membranes that must be traversed before reaching a target. Chemical



barriers include, but are not limited to, pH variations, lipid bi-layers, and degrading enzymes.

These barriers are of particular significance in the design of oral delivery systems. Oral delivery of many biologically or chemically active agents would be the route of choice for administration to animals if not for biological, chemical, and physical barriers such as varying pH in the gastro-intestinal (GI) tract, powerful digestive enzymes, and active agent impermeable gastro-intestinal membranes. Among the numerous agents which are not typically amenable to oral administration are biologically or chemically active peptides, such as calcitonin and insulin; polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents are rapidly rendered ineffective or are destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes, or the like.

Earlier methods for orally administering vulnerable pharmacological agents have relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g., pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic degradation.

Liposomes have also been described as drug delivery systems for insulin and heparin. See, for example, U.S. Patent No. 4,239,754; Patel et al. (1976), *FEBS Letters*, Vol. 62, pg. 60; and Hashimoto et al. (1979), *Endocrinology Japan*, Vol. 26, pg. 337.

However, broad spectrum use of such drug delivery systems is precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. active agents, are not


available; (3) the systems exhibit poor stability and inadequate shelf life; (4) the systems are difficult to manufacture; (5) the systems fail to protect the active agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.

5 More recently, microspheres of artificial polymers of mixed amino acids (proteinoids) have been used to deliver pharmaceuticals. For example, U.S. Patent No. 4,925,673 describes drug-containing proteinoid microsphere carriers as well as methods for their preparation and use. These proteinoid microspheres are useful for the delivery of a number of active agents.

10 There is still a need in the art for simple, inexpensive delivery systems which are easily prepared and which can deliver a broad range of active agents.


SUMMARY OF THE INVENTION

15 Compounds and compositions which are useful in the delivery of active agents are provided. These compositions include at least one active agent, preferably a biologically or chemically active agent, and at least one of the following compounds 1-193, or salts thereof.




1

6-N-(3,5-dichloro-2-hydroxybenzoyl)aminocaproic acid




2

8(2-aminobenzoylamino)caprylic acid




3

8(2-(trifluoromethoxy)benzoylamino)caprylic acid




4

N-(2-hydroxybenzoyl)isonipecotic acid




5

4-{4-(2-aminobenzoylamino)phenyl}butyrylhydroxamic acid




6

4-(4-(pentafluorobenzoyl)aminophenyl)butyric acid




7

4-(4-(3-anisoyl)aminophenyl)butyric acid




8

8-(3-anisoyl)aminocaprylic acid




9

4-(4-(phenoxyacetyl)aminophenyl)butyric acid



10


4-(4-(2-nitrobenzenesulfonyl)aminophenyl)butyric acid



11


8-(2-nitrobenzenesulfonyl)aminocaprylic acid

6




6-(4-(salicyloyl)aminophenyl)hexanoic acid

12




8-(2-methoxybenzoyl)amino caprylic acid

13




2-[(4-salicyloyl)aminophenyl]ethyl methyl sulfone

14




1-salicyloyl-2-succinyl hydrazide

15




3-(4-(2,5-dimethoxycinnamoyl)aminophenyl)propionic acid

16




4-(4-(2,5-dimethoxycinnamoyl)aminophenyl)butyric acid

17




18

1-salicyloyl-2-glutaryl hydrazide




19

4-((4-carboxyl-3-hydroxy phenyl)amino)succinyl)aminosalicylic acid




20

8-(Phenoxyacetyl)aminocaprylic acid




21

8-(2-pyrazinecarbonyl)aminocaprylic acid




22

4-(4-(2-pyrazinecarbonyl)aminophenyl)butyric acid




23

6-(4-(N-(2-Nitrobenzoyl)aminophenyl)hexanoic acid




24

6-(4-(N-(2-aminobenzoyl)aminophenyl)hexanoic acid




25

4-(4-(N-(6-carboxyl-2,5-pyrazinyl(carboxyl)aminophenyl)butyric acid



26


4-(2-Nitrobenzoyl)aminophenylsuccinic acid




27

8-(2-(trifluoromethoxy)benzoyl)aminocaprylic acid


9




28




29



30




31

2-[4-(2-Methoxybenzoylamino)phenyl]ethyl H_2PO_4 

32


1-salicyloyl-2-suberyl hydrazide



33


4-(4-benzyloxycarbonylamino)phenylbutyric acid

10




34

4-(4-(2-hydroxynicotinoyl)aminophenyl)butyric acid




35

9-Salicyloylaminononanoic acid




36

4-(4-phenyloxycarbonylamino)phenyl)butyric acid




37

3-(2-methoxybenzoylamino)-1-propanol



38

8-(2-Hydroxynicotinoyl)aminocaprylic acid




39

6-(2-methoxybenzoylamino)nicotinic acid

WHAT WE CLAIM IS:**507275**

1. A composition comprising:
- (A) at least one active agent; and
- (B) a compound having the formula



or a salt thereof.

2. The composition of claim 1, wherein the active agent is selected from the group consisting of biologically active agents, chemically active agents, and any combination thereof.

3. The composition of claim 2, wherein the biologically active agent comprises at least one peptide, mucopolysaccharide, carbohydrate, or lipid.

4. The composition of claim 2, wherein the biologically active agent is selected from the group consisting of human growth hormones, bovine growth hormones, growth hormone-releasing hormones, interferons, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial natriuretic factor, antigens, monoclonal antibodies, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, and any combination thereof.

INTELLECTUAL PROPERTY
OFFICE OF N.Z.
17 SEP 2001
RECEIVED

507275

1 5. The composition of claim 4, wherein the biologically active agent comprises
2 interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin
3 calcitonin, oxytocin, vasopressin, vancomycin, desferrioxamine, parathyroid hormone,
4 any combination thereof.

1 6. The composition of claim 5, wherein said biologically active agent comprises
2 parathyroid hormone.

1 7. A dosage unit form comprising

2 (A) the composition of any of claims 1 to 6; and

3 (B) (a) an excipient,

4 (b) a diluent,

5 (c) a disintegrant,

6 (d) a lubricant,

7 (e) a plasticizer,

8 (f) a colorant,

9 (g) a dose vehicle, or

10 (h) any combination thereof.

1 8. The dosage unit form of claim 7, comprising a tablet, a capsule, or a liquid.

2 9. The dosage unit form of any of claims 7 and 8, wherein a dose vehicle is
3 selected from the group consisting of water, 1,2-propanediol, ethanol, and any combination
thereof.

1 10. A method for administering a biologically-active agent to an animal, said method
2 comprising administering orally, intranasally, sublingually, intraduodenally,
3 subcutaneously, rectally, vaginally, buccally or ophthalmically to said animal the
4 composition of any of claims 1 to 6, wherein said method is not for medical treatment of
humans.


INTELLECTUAL PROPERTY
OFFICE OF N.Z.

17 SEP 2001

RECEIVED

507275

11. A compound having the formula



or a salt thereof.

12. A method for preparing a composition, said method comprising mixing:

- (A) at least one active agent;
- (B) the compound of claim 11; and
- (C) optionally, a dosing vehicle.

13. A method for passing a biologically active agent across the blood/brain barrier of an animal, said method comprising administering to said animal the composition of any claims 1 to 6, wherein said method is not for medical treatment of humans.

End of claims

-JPL

INTELLECTUAL PROPERTY
OFFICE OF N.Z.

17 SEP 2001

RECEIVED

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.